Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...

Biopharma company AbbVie will acquire Capstan Therapeutics for up to $2.1 billion in cash, giving it access to promising new ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.